Cyclerion stock cut in half after disappointing sickle cell trial results By: Boston Business Journal via Business Journals October 14, 2020 at 11:39 AM EDT The Cambridge biotech has stopped work on its sophomore drug after it exhibited a lackluster effect in a 70-person study. Read More >>